UVA1, Cold-Light UVA1 and UVA/UVB in 70 People With Severe Eczema

November 10, 2026

Research focus: prospective randomized comparison of medium-dose UVA1, cold-light UVA1 and combined UVA/UVB in 70 people with severe atopic dermatitis. This evidence review explains what was measured, how strong the comparison was and which safety questions remain. It is educational and does not prescribe an ultraviolet dose, treatment schedule or home device.

Key finding: The three courses produced different completion and response patterns, with more early discontinuation in the combined UVA/UVB group. [1] Main limitation: Treatment devices and dosing reflect an older technology era, group sizes were unequal, and dropout can distort apparent efficacy.

What medical phototherapy is

Medical phototherapy uses calibrated ultraviolet wavelengths under a clinician-directed protocol. Narrowband UVB centers near 311–313 nm; broadband UVB spans a wider range; UVA1 uses longer wavelengths; PUVA combines a photosensitizing psoralen with UVA; excimer devices target localized areas near 308 nm. These are not interchangeable with sunlight, tanning beds or consumer lamps. [2] [3]

Protocols usually consider diagnosis, skin phototype, minimum erythema response, medications, previous ultraviolet exposure, body site, eye protection and dose adjustments after redness or missed visits. A study’s wavelength and cumulative exposure matter as much as the label “light therapy.” [4] [5]

How this study was designed

This was a prospective randomized comparison of medium-dose UVA1, cold-light UVA1 and combined UVA/UVB in 70 people with severe atopic dermatitis. Randomization strengthens a comparison, but small trials remain imprecise. Split-body studies control for many person-level factors, yet one treated side may influence the other. Cohorts reflect routine practice but cannot fully separate treatment effects from disease fluctuation, concurrent topical care or referral patterns.

Design feature	What it helps answer	Important limitation
Randomized parallel trial	Average difference between assigned regimens	May be small or short
Crossover or half-side study	Within-person comparison	Carryover or spillover
Prospective biomarker study	Timing of molecular change	Marker change is not clinical causation
Retrospective cohort	Routine-care outcomes and uncommon events	Confounding and coding error
Home-device study	Adherence and convenience	Selection and self-report bias

What the investigators found

The three courses produced different completion and response patterns, with more early discontinuation in the combined UVA/UVB group. [1] Other trials show that response varies by wavelength, dose, disease phase and outcome measure. Short-term improvement in EASI or SCORAD does not automatically predict a long remission, and within-group change is not the same as superiority over a comparator. [6] [7]

Mechanistic studies report changes in inflammatory transcripts, epidermal markers, vitamin D and skin microbial composition during treatment. These observations can generate hypotheses, but none is a validated test for choosing a wavelength or forecasting an individual response. [8] [9]

Benefits and burdens that matter to patients

Potential benefits include reduced signs, itch and sleep disruption without continuous systemic-drug exposure. Burdens include repeated travel, time away from work or school, copayments, undressing, eye protection and adherence to a multiweek schedule. Real-world cost and quality-of-life studies show why convenience can affect completion as much as efficacy. [10] [11]

Targeted excimer treatment may spare uninvolved skin when disease is localized; full-body cabinets may be more practical for widespread disease. Home devices can reduce travel but require training, reliable dosing, monitoring and secure storage away from children. [12] [13]

What the evidence does not prove

Treatment devices and dosing reflect an older technology era, group sizes were unequal, and dropout can distort apparent efficacy. Phototherapy studies often use small samples, different scoring systems and varied background topical treatment. A “no significant difference” result can mean comparable effects, insufficient power or both. Absence of a detected cancer signal is reassuring but cannot prove zero lifetime risk. [14] [15]

Results from adults with severe generalized disease should not be transferred automatically to babies, localized eyelid eczema, pregnancy or immunocompromised patients. Findings from one cabinet, lamp spectrum or dosimetry protocol also do not validate another device. [16] [17]

Safety boundaries

Phototherapy requires medical dosing. Do not substitute tanning beds, unregulated lamps or intentional sunburn.
Eye and genital protection matter. Follow the unit’s protocol during every exposure; facial or eyelid disease needs specialist planning.
Report burns and flares. Painful redness, blistering, marked dryness or worsening eczema can require dose adjustment or interruption.
Review photosensitizing medicines. Antibiotics, retinoids, diuretics, herbal products and other agents may change light sensitivity.
Infection needs assessment. Fever, rapidly spreading pain, clustered blisters, honey-colored crust or eye involvement warrants prompt care rather than another light session.
Children need specialist oversight. Cumulative lifetime exposure, cooperation, eye protection and alternatives should be discussed with pediatric dermatology.
PUVA has additional precautions. Psoralen exposure, nausea, eye protection, pregnancy considerations and cumulative UVA risk differ from UVB-only care.

How to interpret laboratory and microbiome findings

Clinical improvement can occur alongside lower relative Staphylococcus aureus, altered cytokine transcripts or changing vitamin D. These are associations within a treatment course. Relative microbial abundance can change because inflammation, topical therapy or total bacterial load changed; a blood or biopsy marker can move without mediating the benefit. [18] [19] [20]

A stronger mechanism claim would require prespecified mediation analysis, repeated absolute measurements and evidence that deliberately changing the marker alters the clinical outcome. Until then, biomarkers should not be used to sell supplements, microbiome products or unvalidated home light devices.

Questions to ask a phototherapy clinic

Which wavelength and device are being proposed, and why?
How is the starting dose chosen and adjusted?
Which medications or supplements increase photosensitivity?
What eye, face and genital protection is required?
How many visits are expected, and how will response be measured?
What happens after missed visits, redness, infection or a flare?
How is cumulative exposure recorded?
When should treatment stop or switch?

Where Dr. Arsy #003 fits—and where it does not

Dr. Arsy #003 was not the product studied in this research. No result about UVB, UVA1, PUVA, excimer light, saltwater bathing, vitamin D, prescription therapy or microbiome change should be transferred to #003. #003 is a cosmetic moisturizer for dry, sensitive, eczema-prone skin. It is not phototherapy, sunscreen, a drug or a light-protection product and is not claimed to treat, cure or prevent eczema.

People seeking a fragrance-free moisturizer for routine cosmetic hydration can view the actual 4-oz Dr. Arsy Moisturizer #003. When phototherapy is prescribed, ask the treating clinic when moisturizer should be applied relative to a session; products can affect optical exposure, comfort and equipment protocols.

Bottom line

This study adds one piece to the phototherapy evidence base. The responsible conclusion depends on its comparator, wavelength, dose, population, follow-up and outcome—not simply whether scores improved. Current guidelines place phototherapy among clinician-directed options when topical care is insufficient, with individualized safety review and monitoring. [21] [18]

Related Dr. Arsy research articles

References

← Back to Doctor's Notes